Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 6/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | NEK2 | P51955 | 1/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.45 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13994272 | 0.93 | MET (0.62) | METMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL13994285 | 0.90 | MET (0.57) | METMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL13247205 | 0.90 | MET (0.76) | METMEN1KMT2APOLB | |
| SCHEMBL13994271 | 0.89 | MET (0.62) | METMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL13994592 | 0.87 | MET (0.61) | METMEN1KMT2ACHEK1NEK2 | |
| SCHEMBL13994337 | 0.87 | MET (0.59) | METMAPT | |
| SCHEMBL13994577 | 0.86 | MET (0.55) | MET | |
| SCHEMBL13994340 | 0.85 | MET (0.59) | METMEN1KMT2A | |
| SCHEMBL15417145 | 0.85 | MET (0.54) | MET | |
| SCHEMBL13994279 | 0.84 | MET (0.51) | METMEN1KMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008145243-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |